To study the effect of valsartan on renin-angiotensin system (RAS) of chronic hepatitis and liver cirrhosis 54chronic hepatitis and liver cirrhosis patients were randomly divided into two groups: therapy group and control group. 27 cases in each group. The control group was treated with routine treatment, the therapy group, besides routine treatment, was added valsartan 80mg/day. The therapy period is 1 month. Before and after treatment, serum renin (PRA) ?angiotensin Ⅱ (AⅡ) ?aldosterone (ALD) were measured by radioimmunoassay. In therapy group, before and after therapy, 5 cases of chronic hepatitis patients' liver tissue were obtained by liver biopsy, then semi-quantity RT-PCR method was used to measure the expression of liver tissue angiotensinogen mRNA?angiotensin Ⅱ type Ⅰ receptor mRNA. As a result, in therapy group, after treated with valsartan, the PRA?AⅡ were elevated remarkably (P<0.05) , ALD was lower (P<0.05) ?In therapy group, the patients' PRA?AⅡ were all elevate significantly (P<0.01) , the ALD was decreased (P<0.001) ;after treated by valsartan, the expression of liver tissue angiotensinogen mRNA?angiotensin Ⅱ type Ⅰ receptor mRNA were all lower than before (P<0.05) . So valsartan can modulate the patients' circulation and local liver tissue renin-angiotensin system, thus inhibit the overactive of the renin-angiotensin-aldosterone system in patients with chronic hepatitis and liver cirrhosis.